BY DAN
WITTERS NOVEMBER 12, 2019
STORY
HIGHLIGHTS
·
34 million adults know
someone who died after not getting treatment
·
58 million adults
report inability to pay for needed drugs in past year
·
Little progress seen
by Trump administration in limiting rising drug costs
Editor's Note: The research detailed below was
conducted in partnership with West Health, a family of nonprofit and
nonpartisan organizations focused on lowering healthcare costs for seniors.
WASHINGTON, D.C. -- More than 13% of American
adults -- or about 34 million people -- report knowing of at least one friend
or family member in the past five years who died after not receiving needed
medical treatment because they were unable to pay for it, based on a new study
by Gallup and West Health. Nonwhites, those in lower-income households, those
younger than 45, and political independents and Democrats are all more likely
to know someone who has died under these circumstances.
Knowledge of Deaths in Last Five Years After
Inability to Pay for Needed Treatment
"Has there been a time in the last five
years when a friend or family member passed away after not receiving treatment
for their condition due to their inability to pay for it?"
|
YES %
|
|
|
U.S.
TOTAL
|
13.4
|
|
Race
|
|
|
White
|
9.6
|
|
Nonwhite
|
20.3
|
|
Annual
household income
|
|
|
Under $40,000
|
18.5
|
|
$40,000
to <$100,000
|
11.1
|
|
$100,000+
|
9.1
|
|
Age
|
|
|
18-44
|
16.9
|
|
45-64
|
12.4
|
|
65+
|
6.6
|
|
Party
ID
|
|
|
Independent
|
16.4
|
|
Democrat
|
14.8
|
|
Republican
|
4.9
|
These data are based on surveys with 1,099 U.S.
adults across all 50 states and the District of Columbia, conducted Sept.
16-30, 2019. Respondents were asked, "Has there been a time in the last
five years when a friend or family member passed away after not receiving
treatment for their condition due to their inability to pay for it?" These
results are not meant to quantify the number of people who have died after not
being able to pay for medical treatment, including prescription drugs, but
rather the number of people who report knowledge of a death under such
circumstances. In all, the Centers for Disease Control and Prevention estimate
that about 2.8
million persons died in 2017 in the U.S. across all causes.
Dovetailing with these results is a rising
percentage of adults who report not having had enough money in the past 12
months to "pay for needed medicine or drugs that a doctor prescribed"
to them. This percentage has increased significantly, from 18.9%
in January 2019 to 22.9% in September. In all, the 22.9% represents
about 58 million adults who experienced "medication insecurity,"
defined as the inability to pay for prescribed medication at least one time in
the past 12 months. The increase reflects a marked rise among women of over
five percentage points to 27.5%, widening the gender gap to over nine points
when compared with the 18.1% rate for men. And while data among both political
independents and Republicans are statistically unchanged since September,
medication insecurity among Democrats has risen over six points to 27.7%.
U.S. Medication Insecurity, January and
September 2019, by Gender and Party ID
"Has there been a time in the last 12
months when your household has been unable to pay for medicine or drugs that a
doctor had prescribed for you because you didn't have enough money to pay for
them?" (% Yes)
|
January
2019
|
September
2019
|
Change
|
|
|
%
|
%
|
pct. pts.
|
|
|
U.S.
Total
|
18.9
|
22.9
|
+4.0*
|
|
Gender
|
|||
|
Male
|
15.2
|
18.1
|
+2.9
|
|
Female
|
22.3
|
27.5
|
+5.2*
|
|
Party
ID
|
|||
|
Independent
|
14.5
|
17.0
|
+2.8
|
|
Democrat
|
21.0
|
27.7
|
+6.7*
|
|
Republican
|
20.3
|
23.1
|
+2.5
|
Gallup-West
Health National Healthcare Study, January 2019 (N=3,537) And September 2019
(N=1,099)
Republicans See Much
More Progress Than Others on Drug Costs
Against a backdrop of millions of Americans who
know people who have died after not being able to afford needed treatment, and
millions more recently experiencing medication insecurity personally, most
respondents agree that U.S. consumers are paying too much for prescription
drugs. Close to nine in 10 U.S. adults report that the costs of prescription
drugs are "usually much higher" (69%) or "tend to be somewhat
higher" (20%) than what consumers should be paying for them, compared with
only 1% who believe them to be much or somewhat lower. These perceptions are
shared by political and demographic subgroups, with only modest differences
between groups in the percentage viewing drug prices as too high.
Americans' Assessments of U.S. Prescription Drug
Prices, by Party ID
"Based on everything you have read and
experienced, please indicate which of the following statements most closely
align with your opinion regarding the cost of prescription drugs in the
U.S.?"
|
U.S. total
|
Repub.
|
Ind.
|
Dem.
|
Approve of Trump
|
Disapprove of Trump
|
|
|
%
|
%
|
%
|
%
|
%
|
%
|
|
|
Usually
much higher than what consumers should be paying
|
69
|
64
|
66
|
76
|
64
|
74
|
|
Tend to be somewhat higher
|
20
|
22
|
21
|
16
|
20
|
19
|
|
About
right
|
9
|
12
|
10
|
6
|
13
|
6
|
|
Tend to be somewhat lower
|
1
|
0
|
1
|
0
|
0
|
0
|
|
Usually
much lower than what consumers should be paying
|
1
|
0
|
1
|
1
|
0
|
1
|
|
Gallup-West
Health National Healthcare Study, Sept. 16-30, 2019; N=1,099
|
||||||
While perspectives on the price of medicine
relative to what consumers should be spending are largely uniform, perspectives
regarding President Donald Trump's success at curtailing rising drug prices are
more divided along party lines. When asked, "How much progress has the
Trump administration made to limit the rising cost of prescription drugs in the
U.S.?" two-thirds of respondents -- split evenly -- report "not very
much" progress or "none at all." But only 31% of Republicans
express this sentiment, compared with 66% of independents and 96% of Democrats.
Nearly nine out of 10 adults who disapprove of the job Trump is doing also
report little to no progress.
Evaluation of Trump Administration on Curtailing
Rising Costs of Prescription Drugs, by Party ID
"How much progress has the Trump
administration made to limit the rising cost of prescription drugs in the U.S.
-- a great deal, a fair amount, not very much or none at all?"
|
U.S.
total
|
Republican
|
Independent
|
Democrat
|
Approve
of Trump
|
Disapprove
of Trump
|
|
|
%
|
%
|
%
|
%
|
%
|
%
|
|
|
A
great deal
|
7
|
14
|
6
|
2
|
13
|
3
|
|
A fair amount
|
20
|
49
|
16
|
1
|
43
|
5
|
|
Not
very much
|
33
|
25
|
34
|
39
|
29
|
37
|
|
None at all
|
33
|
7
|
32
|
57
|
7
|
51
|
|
Not
very much/None at all
|
66
|
31
|
66
|
96
|
35
|
88
|
|
Gallup-West Health
National Healthcare Study, Sept. 16-30 2019; N=1,099
|
||||||
Bottom Line
The substantial number of Americans who know
someone who has died after not receiving treatment because of their inability
to pay for it, coupled with the rise in the percentage who have not had enough
money to pay for their prescriptions, underscores the urgency of the U.S.
healthcare cost crisis. These realities starkly highlight the significant
practical implications of drug prices on U.S. residents, as well as the effects
of healthcare policy action -- or inaction.
With millions of residents knowing someone who
has died in the past five years after being unable to pay for needed treatment,
the ramifications to public trust in the U.S. healthcare system could be
significant. This erosion of trust is likely exacerbated by the estimated 58
million adults who have themselves been unable to afford prescribed drugs at
least once in the last 12 months. The level of medication insecurity is high
and rising, and is doing so against a backdrop of overwhelming public sentiment
regarding the inappropriately high prices of prescription drugs. The rise in
reported 12-month medication insecurity among women and Democrats dovetails with rising
uninsured rates for related subgroups over the course of 2018, and
could be, in part, a reflection of the decreased coverage among these
constituencies.
Drug prices directly affect consumers, and with
the U.S. one year away from the 2020 election, presidential candidates will
increasingly be asked to explain and defend their policy positions regarding
rising drug costs. Only 7% of U.S. adults report that the Trump administration
has accomplished "a great deal" on the issue, and voters are clearly
expecting more from their elected officials than what has been accomplished in
the past three years. In Congress, meanwhile, the U.S. House of Representatives
is expected to vote soon on House Democrats' plan to curb soaring prescription
drug prices by allowing the federal government to negotiate prices of certain
drugs, including insulin products and single-source brand-name drugs with no
generic competition. The U.S. Senate is considering a separate, bipartisan
proposal that would cap seniors' out-of-pocket costs and require drug
manufacturers to reimburse Medicare if prices rise more than the inflation
rate.
Given these ongoing challenges, West Health and
Gallup have committed to measuring public opinion on a wide array of issues
relevant to healthcare costs on a recurring basis, providing stakeholders and
policymakers with the information they need to gauge whether progress is being
made on these most critical issues of our time.
This is a very useful post, thank you! I agree that innovations are the most important thing for most businesses, because with today’s fast changing world we need to stay on top of the changes, if we want to survive.
ReplyDeleteChronic Headache Treatments